Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting
24 oct. 2023 09h00 HE
|
Cascade Prodrug Inc.
Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
14 sept. 2023 09h41 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Hypoxia Market Growing Significantly, Assesses DelveInsight | Teclison Ltd., Merck, Eli Lilly and Company, Reven Pharmaceuticals, Biogen Expected to Boost Hypoxia Market
10 avr. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, April 10, 2023 (GLOBE NEWSWIRE) -- Hypoxia Market Growing Significantly| Teclison Ltd., Merck, Eli Lilly and Company, Reven Pharmaceuticals, Biogen Expected to Boost Hypoxia Market ...
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
20 déc. 2021 07h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
16 déc. 2021 08h59 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
01 déc. 2021 07h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
22 nov. 2021 07h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
10 nov. 2021 07h02 HE
|
Diffusion Pharmaceuticals Inc.
Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
Diffusion Pharmaceuticals Issues Letter to Shareholders
09 sept. 2021 07h32 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
08 sept. 2021 07h32 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...